Drug Eluting Stent Market to Grow with a CAGR of 8.08% through 2030
Aging Global Population and Rising Prevalence of Cardiovascular Diseases (CVDs) are factors driving the Global Drug Eluting Stent Market in the forecast period 2026-2030
According to TechSci Research report, “Drug Eluting
Stent Market – Global Industry Size, Share, Trends, Competition Forecast
& Opportunities, 2030”, the Global Drug Eluting Stent Market stood at
USD 8.30 Billion in 2024 and is anticipated to grow with a CAGR of 8.08% in the
forecast period, 2026-2030.
The global drug-eluting stent (DES) market has witnessed significant growth, driven by the increasing prevalence of cardiovascular diseases (CVDs), technological advancements, and rising healthcare investments. As coronary artery disease (CAD) becomes more widespread due to sedentary lifestyles, poor dietary habits, and an aging global population, the demand for minimally invasive treatment options has surged. Drug-eluting stents have emerged as a preferred solution, offering improved patient outcomes and reducing the need for complex surgical interventions.
One of the key factors fueling market expansion is the continuous evolution of stent technology. Manufacturers are focusing on enhancing drug-elution mechanisms, improving biocompatibility, and developing bioresorbable stents that dissolve over time, eliminating concerns associated with permanent implants. These innovations have positioned DES as a superior alternative to bare-metal stents (BMS) and conventional angioplasty, driving adoption among healthcare providers. Additionally, the increasing shift toward percutaneous coronary interventions (PCI) over traditional bypass surgeries has further accelerated DES demand. Minimally invasive procedures are gaining traction due to their shorter recovery times, reduced hospital stays, and lower post-procedural complications, making DES a critical component of modern interventional cardiology.
Healthcare infrastructure investments in both developed and emerging economies are also playing a crucial role in DES market expansion. Governments and private healthcare providers are allocating substantial budgets to improve access to advanced cardiovascular treatments, leading to higher DES adoption rates worldwide. Furthermore, increasing awareness campaigns and educational initiatives have contributed to a growing preference for DES among both patients and physicians. As the global healthcare industry continues to emphasize early diagnosis and efficient treatment of CAD, drug-eluting stents are expected to witness sustained market growth. With ongoing innovations and expanding healthcare access, DES adoption will remain a key driver of advancements in interventional cardiology.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "Global Drug Eluting Stent Market”
The Global Drug Eluting Stent
Market is segmented into Coating Type, Application, Regional Distribution and company.
Based on its application, The Coronary artery disease (CAD) segment is projected to experience rapid growth during the forecast period. CAD is one of the most common heart diseases worldwide, affecting millions of people. It occurs when the arteries that supply blood to the heart become narrowed or blocked due to the buildup of plaque. This high prevalence of CAD ensures a large patient population in need of treatment, which drives demand for drug-eluting stents. Drug-eluting stents have proven to be highly effective in treating CAD. They are used to open narrowed or blocked coronary arteries, restore blood flow to the heart, and prevent the recurrence of blockages. Their ability to reduce restenosis (the re-narrowing of arteries) compared to bare-metal stents makes them a preferred choice in CAD treatment. Over the years, there have been continuous advancements in drug-eluting stent technology. New stents are designed to release drugs that inhibit cell growth and inflammation at the stent site, further reducing the risk of restenosis. These technological innovations make DES a compelling option for CAD treatment.
Based on region, The Asia-Pacific region is poised to experience the fastest growth in the global drug-eluting stent (DES) market, driven by rapid economic development, rising cardiovascular disease prevalence, increasing healthcare investments, and expanding medical infrastructure. As governments and private sector players focus on improving access to advanced cardiac treatments, DES adoption is set to accelerate across the region. Asia-Pacific is witnessing a sharp increase in coronary artery disease (CAD) cases, fueled by urbanization, unhealthy dietary habits, sedentary lifestyles, and high smoking rates. Countries like China, India, and Japan report some of the highest CVD mortality rates globally, making drug-eluting stents a critical treatment solution. The growing burden of hypertension, diabetes, and obesity key risk factors for CAD is further increasing the demand for minimally invasive cardiac interventions, including percutaneous coronary intervention (PCI) with DES. Governments across China, India, South Korea, and Southeast Asian nations are making large-scale investments in healthcare infrastructure, enhancing cardiac care facilities and expanding patient access to advanced interventional cardiology treatments.
Major companies operating in
Global Drug Eluting Stent Market are:
- Abbott Laboratories ltd.
- Boston Scientific Corporation
- Terumo Corporation
- Medtronic plc
- Biosensors International Ltd
- Cook Medical pvt ltd.
- B. Braun Medical (India) Private Limited
- Biotronik, Inc.
- Lepu Medical Technology Inc.
Download Free Sample Report
Customers can also request 10% free
customization in this report.
“The global drug-eluting stent market is poised for
continued growth due to the convergence of several key drivers. The increasing
prevalence of cardiovascular diseases, technological innovations, the
popularity of minimally invasive procedures, the aging population, healthcare
spending, education, and reimbursement policies are all contributing to the
expansion of this vital medical device market. As these factors continue to
evolve, the market for drug-eluting stents is expected to advance, providing better
treatment options and improved outcomes for patients with coronary artery
disease and other cardiovascular conditions.,” said Mr. Karan Chechi, Research
Director of TechSci Research, a research-based management consulting firm.
“Drug Eluting Stent Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Coating Type (Polymer-based Coatings (Non-biodegradable, Biodegradable)), Polymer-free Coatings(Micro porous Surface, Micro structured Surface, Slotted tubular Surface, Nanoporous Surface)), By Application (Coronary Artery Disease, Peripheral Artery Disease), By Region & Competition, 2020-2030F”, has evaluated the future growth potential of Global
Drug Eluting Stent Market and provides statistics & information on market
size, structure and future market growth. The report intends to provide
cutting-edge market intelligence and help decision makers take sound investment
decisions. Besides, the report also identifies and analyzes the emerging trends
along with essential drivers, challenges, and opportunities in Global Drug
Eluting Stent Market.
Contact
TechSci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel: +1-332-258-6602
Email: sales@techsciresearch.com
Website: www.techsciresearch.com